Researchers Map Parasite Mitochondria to Uncover Dozens of Potential New Drug Targets

An extensive international research effort spanning multiple top-tier institutions has successfully mapped the full set of mitochondrial proteins across several deadly parasites. Published across a series of papers in journals including Cell and Current Biology, the findings reveal ancient cellular pathways and offer promising new directions for developing medications to combat widespread tropical and systemic illnesses.

Led by Howard Hughes Medical Institute (HHMI) investigator Vamsi Mootha, a consortium of 25 scientists from organizations such as the Harvard T.H. Chan School of Public Health, Harvard Medical School, the Broad Institute, Massachusetts General Hospital, and Boston University spent four years investigating the mitochondrial proteomes of dangerous pathogens. These include the organisms responsible for sleeping sickness, giardiasis, leishmaniasis, and babesiosis—diseases that collectively impact nearly one billion people globally each year.

To establish a uniform and reliable baseline across diverse species, the research team utilized a technique known as protein correlation profiling. By fragmenting the cells of each organism and employing mass spectrometry, the investigators tracked which proteins consistently associated with known mitochondrial components. This meticulous workflow allowed the consortium to catalogue the mitochondrial proteins of five major eukaryotic organisms, identifying previously unknown structural and functional components.

Targeting Shared Parasitic Machinery

Mitochondria, widely recognized as the cellular powerhouses responsible for generating energy, have previously served as successful therapeutic targets. For example, the medication atovaquone combats the malaria-causing parasite Plasmodium falciparum by disrupting a specific mitochondrial protein. Building upon this established pharmacological concept, Mootha and his colleagues searched for protein families that are shared among the mitochondria of multiple disease-causing pathogens.

Crucially, for a protein family to serve as a viable therapeutic target, it must be absent from human mitochondria to prevent adverse toxicity in patients. By cross-referencing their data, the consortium identified 33 distinct protein families that appear across two or more of the studied parasites while remaining entirely missing from human cells. These shared protein networks represent foundational candidates for broad-spectrum medications capable of treating multiple parasitic infections simultaneously.

Study authors emphasize that these discoveries remain in early preclinical stages. Substantial developmental work is required to transition from identifying a molecular target to formulating safe, effective pharmaceutical treatments for human patients.

Redefining Cellular Biology and Evolution

Beyond drug discovery, the expansive mapping project challenges standard textbook models of mitochondrial biology, which have historically relied heavily on human and yeast cells. By investigating more specialized and unusual organisms, the researchers observed organelles that completely break conventional aerobic paradigms.

For instance, the organism that causes giardiasis features mitochondria that have entirely lost their signature DNA. Despite this genetic loss, the organelle maintains a minimal structure containing 59 proteins, many of which still have unknown functions. Conversely, Acanthamoeba displays a much more complex mitochondrial network that utilizes an enzyme called hydrogenase as a backup power source, enabling the organelle to produce hydrogen gas when oxygen levels decline.

By integrating their new empirical data with established evolutionary biology, the team reconstructed a model of the mitochondrion belonging to the last common ancestor of all eukaryotes (LECA). The resulting analysis indicates that ancestral mitochondria were remarkably sophisticated and metabolically flexible, capable of generating energy regardless of oxygen availability. Investigators note that modern human mitochondria have actually lost many of these ancient, versatile pathways over the course of evolution.

The consortium has made its comprehensive dataset publicly available to the scientific community. Researchers hope these detailed inventories will accelerate future investigations into microbial biochemistry and expand the horizon of targeted antimicrobial treatments.

Source: Medical Xpress